Bright Minds BiosciencesDRUG
13F holders, Q3 2024 (September 30)6holders
1new positions
1sold out
$1.20avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding Bright Minds Biosciences Inc. (DRUG) in their 13F filings, unchanged from Q2 2024. 1 opened new positions and 1 sold out. The largest holders were AdvisorShares Investments LLC ($219K), National Bank of Canada ($6K) and UBS Group AG ($4K).
- Company
- Bright Minds Biosciences Inc.
- CUSIP
- 10919W405
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 1 | $12K |
All 13F filers, Q2 2024 → Q3 2024: 4,985 shares bought and 10,978 shares sold, net −5,993 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| AdvisorShares Investments LLC | 0.04% | Add +0.8% | 182,420 | $219K |
| National Bank of Canada | 0.00% | Reduce -0.8% | 4,959 | $6K |
| UBS Group AG | 0.00% | New | 3,407 | $4K |
| Royal Bank of Canada | 0.00% | Add +29.4% | 660 | $1K |
| Aspire Private Capital, LLC | 0.00% | No change | 100 | $117 |
| BlackRock, Inc. | 0.00% | — | 1 | $1 |
"% of holder's portfolio" is DRUG's weight in each manager's 13F, not the share of Bright Minds Biosciences Inc. the manager owns.